Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSGJ-612
- Development stage
- Phase 2
- Lead developer
- Shenyang Sunshine Pharmaceutical Co., LTD.
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SSGJ-612 is a **monoclonal antibody** targeting HER2 (Receptor tyrosine-protein kinase erbB-2). It is designed to act as a **HER2 antagonist** with mechanisms including direct receptor antagonism and antibody-dependent cell-mediated cytotoxicity (ADCC). SSGJ-612 is being developed primarily for the treatment of **HER2-positive cancers** and advanced solid tumors that overexpress the HER2 protein, particularly in patients who have progressed on or are ineligible for standard therapies. The drug is currently in Phase 1 clinical trials, evaluating safety, pharmacokinetics, and antitumor activity. It is developed by **Shenyang Sunshine Pharmaceutical** and is one of the first advanced HER2-targeted therapies emerging from China[1][2][3][5][8][10].
- Brand names
- SSGJ-612SSGJ612SSGJ 612
- Other names
- 抗HER2单抗SSGJ-612Anti-HER2 antibodyAnti-HER-2 antibodyAnti-HER 2 antibody612
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SSGJ-612.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSGJ-612.